Safety of exercise after pulmonary endarterectomy: a systematic review, European Respiratory Journal Open Research 2026
A systematic review recently published in the European Respiratory Journal Open Research looked at whether early exercise after pulmonary endarterectomy (PEA) surgery in chronic thromboembolic pulmonary hypertension (CTEPH) is safe and feasible, given that post-operative cardiac remodelling needs to be balanced against the benefits of getting moving early. Searching the…
Read More
Multicentre study explores impaired bone morphogenetic protein receptor 2 (BMPR2) signalling across pulmonary hypertension subgroups, European Respiratory Journal Open Research 2026
A multicentre study recently published on the European Respiratory Journal Open Research looked at bone morphogenetic protein receptor 2 (BMPR2) signalling — a pathway already known to be disrupted in heritable pulmonary arterial hypertension (PAH) — across a wider range of pulmonary hypertension (PH) patients, to see whether the same…
Read More
Tenax Therapeutics announces results from phase 3 LEVEL trial of TNX-103 in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, PH-HFpEF, August 10, 2026
Tenax Therapeutics, Inc. announced today the topline results of its Phase 3 LEVEL trial, which evaluated TNX-103 (oral levosimendan) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF), Group 2 of the World Health Organisation (WHO) pulmonary hypertension classification. The trial did not meet its…
Read More
Live Webinar on Early Referral for Lung Transplantation: Recognizing the Right Time, CHEST, June 2, 2026, recording now available
A live, case-based webinar held on June 2, 2026 looked at when and how patients with advanced pulmonary disease should be referred for lung transplant evaluation. The expert faculty walked through evidence-based referral criteria, disease-specific considerations, and complex scenarios — including interstitial lung disease, pulmonary arterial hypertension, and critically ill…
Read More
“United for better breathing – Co-creating care: patients as equal partners”, European Respiratory Society (ERS) webinar on August 31, 2026, 17:00–18:00 CEST
This European Respiratory Society webinar, chaired by Prof. Hilary Pinnock and Louise Bouman, Vice President of the Alliance for Pulmonary Hypertension and President of the Dutch Pulmonary Hypertension Foundation, is the penultimate session of the pre-Congress webinar series – developed in collaboration with the European Lung Foundation – that introduces the…
Read More
New edition of EMPHASIS, the UK Pulmonary Hypertension Association (PHA UK)’s magazine, August 2026
Here are the main topics covered in this issue of emPHAsis (Issue Two, 2026): Cover feature / Special News and research Personal stories People and professionals Everyday life with PH Regular sections Download pdf at this link
Read More
Climbing for a Cause: Krishma Kaur’s Kilimanjaro Challenge in Support of the UK Pulmonary Hypertension Association – PHA UK -and the Alzheimer’s Society
Krishma Kaur and his cousin Sean Bhaker, UK citizens, have decided to take on the challenge of climbing Mount Kilimanjaro to raise money for Alzheimer’s Society and the UK Pulmonary Hypertension Association PHA UK. All money raised will be donated directly to these two charities. Krishma and Sean have launched…
Read More
Inhaled pulmonary vasodilators in pulmonary hypertension: perioperative use and clinical considerations, Journal of Heart and Lung Transplant, November 2026 edition
A narrative review on inhaled pulmonary vasodilators (iPVs) in perioperative pulmonary hypertension (PH) management was published recently in Key points: Background: Pulmonary hypertension significantly raises perioperative morbidity/mortality risk, especially in cardiac and high-risk non-cardiac surgery. Traditional IV vasodilators (nitroglycerin, sodium nitroprusside) lack pulmonary selectivity and cause systemic hypotension. Established agents:…
Read More
From Warfarin to Viagra: Accidental Medical Discoveries that Have Improved the Lives of Millions Worldwide
he pathway to medical breakthroughs is often laden with surprises, errors, and serendipity, reads and article in a magazine called Mirage. The article dates back to 2023 but we found it still relevant and interesting as it mentions two iaccidental discoveries, warfaring and sildenail citrate that are have transformed the…
Read More
How Do Sleep Difficulties Interact With Anxiety, Depression and Health-Related Quality of Life in Pulmonary Hypertension? – Clinical Respiratory Journal, August 2026
A cross-sectional study surveyed 111 adults with pulmonary hypertension (see table below for different forms), predominantly UK-based, White, and female, to examine sleep problems and their psychological/quality-of-life impact. The design and procedure of the study were developed in association with the UK Pulmonary Hypertension Association, PHA UK, and medical experts…
Read More
World Health Organization opens public consultation on its first global strategy for organ donation and transplant, deadline August 31st 2026
The World Health Organization (WHO) has opened public consultation (until 31 August 2026) on its first draft global strategy for donation and transplantation of human cells, tissues and organs — following up on WHA resolution 77.4 (2024). Key points: Who should participate Policy makers, regulators, service developers-providers, professional bodies, clinical and…
Read MoreInsmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients with Pulmonary Arterial Hypertension, July 16, 2026
Insmed announced on July 16 positive 12-Month data from the ongoing open-label extension (OLE) study evaluating treprostinil palmitil inhalation powder (TPIP), administered once daily in patients with pulmonary arterial hypertension (PAH, World Health Organization Group 1). The OLE study is a non-placebo-controlled trial and was designed to evaluate the long-term…
Read More
What’s new in Pulmonary Hypertension on the Knowledge Sharing Platform in July 2026
This month’s round-up brings together a mix of clinical trial data, emerging science, and a few broader conversations about care. Beyond the data, it also touches on the human side of PH care: a look at quality of life and mental health in patients on prostacyclin therapy, and a conversation…
Read More
The Pulmonary Vascular Research Institute launches the Global PH Consult, a new, free, online service for clinicians which aims to support more equitable access to pulmonary hypertension case discussion and shared learning
The Pulmonary Vascular Research Iinstitute (PVRI’s) Access to Care Workstream has launched a new, free online service from clinicians around the world to bring anonymised complex pulmonary hypertension cases for discussion with a tailored panel of specialists. Global PH Consult is open to clinicians everywhere, with a primary focus on…
Read More
Long-term efficacy and safety of rehabilitation in patients with pulmonary arterial hypertension: the French FONCE-HTAP randomized controlled trial, Annals of American Thoracic Society, July 20, 2026
A French multicenter trial (9 centers, 2015–2022) tested whether a 3-month supervised rehabilitation program improves 12-month exercise capacity in pulmonary arterial hypertension patients, using a Zelen design to limit performance bias — addressing a gap left by prior short-term, open-label studies. Key findings: Conclusion: A 3-month supervised rehabilitation program produced…
Read More
Caring for the whole person, a conversation with Susanne McDevitt, critical care nurse practitioner with the Pulmonary Hypertension (PH) Program, University of Michigan, Ann Arbor
Beyond hemodynamics and treatment targets, there are conversations with patients that rarely make it into clinical guidelines — yet they’re often the ones that matter most. That’s the message from Susanne McDevitt, DNP, a critical care nurse practitioner with the Pulmonary Hypertension (PH) Program at Michigan Medicine, University of Michigan,…
Read More
Quality of Life Outcomes in Patients with Pulmonary Hypertension Receiving Prostacyclin Therapy: Impact of Anxiety, Depression, Sociodemographic Characteristics, and Treatment-Related Factors, Turkish Cardiology Journal, July 6, 2026
A cross-sectional study conducted between July 2023 and September 2024 examined factors affecting quality of life (QoL) in 58 pulmonary arterial hypertension patients on prostacyclin therapy, using validated scales (PAHSS for symptoms, HADS for anxiety/depression, EmPHasis-10 for quality of life). Key findings: Conclusion: Despite prostacyclin therapy, quality of life remains…
Read More
Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review via the Pulmonary Vascular Research Institute (PVRI), Pulmonary Circulation, July 14, 2026
A review recently published in Pulmonary Circulation brings together academic and industry researchers (via the PVRI Innovative Drug Discovery Initiative) to consolidate current knowledge on activin signaling inhibitors (ASIs), the role of specific Bone morphogenetic protein (BMP) ligands, efficacy/safety data, and considerations for developing next-generation activin signaling inhibitors. Key points:…
Read More
Historically Marginalized And Minoritized Populations With Pulmonary Arterial Hypertension: A Deeper Dive Into a Complex Question, CHEST July 14, 2026
In pulmonary arterial hypertension there are significant disparities in epidemiology, clinical outcomes, and healthcare access that disproportionately affect historically neglected populations, including Black Americans, Hispanic Americans, and American Indians. A State-of-the-Art review recently published on CHEST examines the disparities in the three groups. Key points: Conclusion: These disparities stem from structural/socioeconomic…
Read MoreSomething went wrong. Please refresh the page and/or try again.
Archive (1107) News (826) Save the date (5)
AI (3) America (17) Asia (13) biomarkers (3) BMPR2 (3) clinical trials (3) Colombia (3) CTEPH (7) Deutsch (3) diagnosis (9) diagnostics (3) Digital health (3) ELF (3) EMA (3) English (4) ERS (3) ESOT (4) Europe (34) Francais (9) genetics (4) German (4) Germany (3) Greek (2) health technology assessment (3) Hipertensión Pulmonar (2) HTA (3) HTAP (5) Italiano (6) Latinamerica (14) Lungenhochdruck (3) PAH (9) PAHSSc (6) PH (3) PHA (11) PHA UK (8) QOL (3) quality of life (3) remote monitoring (4) RHC (4) right heart catheterisation (3) scleroderma (3) sotatercept (5) Spain (3) Telemedicine (3) Turkish (7)